{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "TNF-\u03b1",
      "VEGF",
      "asthma",
      "exacerbation",
      "virus"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25109477",
  "DateCompleted": {
    "Year": "2015",
    "Month": "07",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/cea.12387"
    ],
    "Journal": {
      "ISSN": "1365-2222",
      "JournalIssue": {
        "Volume": "44",
        "Issue": "12",
        "PubDate": {
          "Year": "2014",
          "Month": "Dec"
        }
      },
      "Title": "Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology",
      "ISOAbbreviation": "Clin Exp Allergy"
    },
    "ArticleTitle": "Nasal lavage VEGF and TNF-\u03b1 levels during a natural cold predict asthma exacerbations.",
    "Pagination": {
      "StartPage": "1484",
      "EndPage": "1493",
      "MedlinePgn": "1484-93"
    },
    "Abstract": {
      "AbstractText": [
        "Asthma exacerbations contribute to significant morbidity, mortality and healthcare utilization. Furthermore, viral infections are associated with asthma exacerbations by mechanisms that are not fully understood.",
        "The aim of this analysis was to determine whether cytokine patterns in patients with colds could identify risks for subsequent asthma exacerbations.",
        "We analysed cytokine levels in nasal lavage fluid (NLF) in 59 subjects (46 with asthma) with acute upper respiratory symptoms and after symptomatic resolution. Analyte choice was based on potential relevance to asthma exacerbations: antiviral (IFN-\u03b1, IFN-\u03b2, IFN-\u03b3, IFN-\u03bb1, IP-10, TRAIL), cell recruiting (G-CSF, IL-1\u03b2, IL-8, MCP-1, MCP-3, TNF-\u03b1), polarizing (CXCL13, IL-10, IL-13, IL-17, TSLP), and injury remodelling (fibronectin, IL-33, MMP-9, VEGF).",
        "The overall cytokine response induced during viral infections was not different between asthmatic and non-asthmatic individuals for a wide array of cytokines. However, mean levels of VEGF, TNF-\u03b1 and IL-1\u03b2 were 1.7-, 5.1- and 4.7-fold higher in samples from asthma subjects who exacerbated in the first 3 weeks of the cold compared with those who did not exacerbate (P = 0.006, 0.01, 0.048, respectively). Using receiver operating characteristic curve-defined thresholds, high VEGF and TNF-\u03b1 levels predicted a shorter time-to-exacerbation after NLF sampling (25% exacerbation rate: 3 vs. 45 days, and 3 vs. 26 days; P = 0.03, 0.04, respectively).",
        "Although they produce similar cytokine responses to viral infection as non-asthmatics, asthmatics with higher levels of VEGF and TNF-\u03b1 in NLF obtained during acute cold phases predicted subsequent asthma exacerbations in this cohort of patients with mild-to-moderate disease. In the future, stratifying the risk of an asthma exacerbation by cytokine profile may aid the targeting of personalized treatment and intervention strategies."
      ],
      "CopyrightInformation": "\u00a9 2014 John Wiley & Sons Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Wisconsin School of Medicine and Public Health, Madison, WI, USA."
          }
        ],
        "LastName": "Manthei",
        "ForeName": "D M",
        "Initials": "DM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Schwantes",
        "ForeName": "E A",
        "Initials": "EA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mathur",
        "ForeName": "S K",
        "Initials": "SK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Guadarrama",
        "ForeName": "A G",
        "Initials": "AG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kelly",
        "ForeName": "E A",
        "Initials": "EA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gern",
        "ForeName": "J E",
        "Initials": "JE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jarjour",
        "ForeName": "N N",
        "Initials": "NN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Denlinger",
        "ForeName": "L C",
        "Initials": "LC"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 HL115118",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U19 AI070503",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 HL080412",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "UL1 TR000427",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "T32 GM008692",
        "Acronym": "GM",
        "Agency": "NIGMS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "TL1 TR000429",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "UL1TR000427",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P01 HL088594",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "U10 HL109168",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "K23 HL081492",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Clin Exp Allergy",
    "NlmUniqueID": "8906443",
    "ISSNLinking": "0954-7894"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cytokines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Tumor Necrosis Factor-alpha"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vascular Endothelial Growth Factor A"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis",
        "etiology"
      ],
      "DescriptorName": "Asthma"
    },
    {
      "QualifierName": [
        "complications",
        "metabolism"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Cytokines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Progression"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Nasal Lavage Fluid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "ROC Curve"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Tumor Necrosis Factor-alpha"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Vascular Endothelial Growth Factor A"
    }
  ],
  "CoiStatement": "<b>CONFLICTS OF INTEREST:</b> DMM, EAS, AGG and EAK have no conflicts of interest. SKM, JEG, NNJ, and LCD are PI or co-PI on NIH grants. SKM is a consultant for TEVA. JEG is a consultant for GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Theraclone, Merck and Gilead. NNJ is a consultant for Boston Scientific and Genentech. LCD is a consultant for Novartis."
}